Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:LPCN
- CUSIP: N/A
- Web: www.lipocine.com
Capitalization:- Market Cap: $87.67 million
- Outstanding Shares: 19,261,000
Average Prices:- 50 Day Moving Avg: $4.03
- 200 Day Moving Avg: $3.87
- 52 Week Range: $3.03 - $5.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.46
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.29 per share
- Price / Book: 3.62
Profitability:- EBIDTA: ($16,260,000.00)
- Return on Equity: -59.98%
- Return on Assets: -55.98%
Debt:- Current Ratio: 11.58%
- Quick Ratio: 11.58%
Misc:- Average Volume: 420,056 shs.
- Beta: 1.88
- Short Ratio: 13.2
Frequently Asked Questions for Lipocine (NASDAQ:LPCN)
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings results on Monday, May, 8th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.04. View Lipocine's Earnings History.
Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?
3 brokerages have issued 1-year price objectives for Lipocine's stock. Their forecasts range from $10.00 to $38.00. On average, they expect Lipocine's share price to reach $24.33 in the next twelve months. View Analyst Ratings for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include Trevena (TRVN), Redhill Biopharma (RDHL), vTv Therapeutics (VTVT), Sorrento Therapeutics (SRNE), Summit Therapeutics PLC (SMMT), Synthetic Biologics (SYN), MannKind Corporation (MNKD), Recro Pharma (REPH), AcelRx Pharmaceuticals (ACRX), Cellular Biomedicine Group (CBMG), OncoCyte Corp (OCX), ProQR Therapeutics N.V. (PRQR), Cidara Therapeutics (CDTX), Axsome Therapeutics (AXSM), Verastem (VSTM), Fate Therapeutics (FATE), Agile Therapeutics (AGRX) and Proteostasis Therapeutics (PTI).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer
- Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President
- Gregory Bass, Executive Vice President, Chief Commercial Officer
- Stephen Anthony Hill M.D., Lead Independent Director
- Jeffrey A. Fink, Director
- Richard Dana Ono, Director
- John W. Higuchi, Non-Executive Director
How do I buy Lipocine stock?
Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of Lipocine stock can currently be purchased for approximately $4.67.
MarketBeat Community Rating for Lipocine (NASDAQ LPCN)MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Lipocine (NASDAQ:LPCN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $24.33 (421.06% upside) |
Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/20/2017 | Roth Capital | Set Price Target | Buy | $38.00 | Low |  |
| 4/26/2017 | HC Wainwright | Reiterated Rating | Buy | $25.00 | Low | |
| 4/24/2017 | Canaccord Genuity | Set Price Target | Buy | $10.00 | High | |
(Data available from 7/20/2015 forward)
Earnings History for Lipocine (NASDAQ:LPCN)Earnings History by Quarter for Lipocine (NASDAQ LPCN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | ($0.30) | ($0.26) | | | View | N/A | |
| 3/6/2017 | Q4 2016 | ($0.28) | ($0.16) | | | View | N/A | |
| 8/9/2016 | Q2 | ($0.37) | ($0.32) | | | View | N/A | |
| 5/9/2016 | Q1 | ($0.33) | ($0.38) | | | View | N/A | |
| 3/10/2016 | Q4 2015 | ($0.29) | ($0.25) | | | View | N/A | |
| 11/12/2015 | Q3 | ($0.35) | ($0.35) | | | View | N/A | |
| 8/11/2015 | Q2 2015 | ($0.20) | ($0.26) | | | View | N/A | |
| 5/7/2015 | Q1 2015 | ($0.35) | ($0.23) | | | View | N/A | |
| 3/11/2015 | Q4 2014 | ($0.35) | ($0.32) | | | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.58) | ($0.32) | | | View | N/A | |
| 8/13/2014 | Q2 2014 | ($0.42) | ($0.55) | | | View | N/A | |
| 5/13/2014 | Q1 2014 | ($0.35) | ($0.41) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Lipocine (NASDAQ:LPCN)2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.20) | ($0.20) | ($0.20) |
| Q2 2017 | 2 | ($0.33) | ($0.31) | ($0.32) |
| Q3 2017 | 2 | ($0.28) | ($0.12) | ($0.20) |
| Q4 2017 | 2 | ($0.30) | ($0.15) | ($0.23) |
| Q1 2018 | 1 | $0.82 | $0.82 | $0.82 |
| Q2 2018 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q3 2018 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q4 2018 | 1 | ($0.39) | ($0.39) | ($0.39) |
(Data provided by Zacks Investment Research)
Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 38.55%
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/30/2015 | John W Higuchi | Director | Buy | 5,000 | $12.68 | $63,400.00 | |
| 9/30/2015 | Mahesh V. Patel | CEO | Buy | 4,000 | $11.84 | $47,360.00 | |
| 11/25/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.10 | $10,200.00 | |
| 11/24/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.45 | $10,900.00 | |
| 11/19/2014 | Richard Dana Ono | Director | Buy | 4,000 | $5.14 | $20,560.00 | |
| 11/14/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.06 | $10,120.00 | |
| 11/13/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.05 | $10,100.00 | |
| 11/13/2014 | Stephen A Hill | Director | Buy | 4,000 | $4.95 | $19,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
| Source: |
|
Lipocine (LPCN) Chart for Thursday, July, 20, 2017
